NASDAQ:NCNA NuCana 3/20/2025 Earnings Report $4.42 -0.55 (-11.03%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast NuCana EPS ResultsActual EPS-$64.00Consensus EPS -$486.00Beat/MissBeat by +$422.00One Year Ago EPSN/ANuCana Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANuCana Announcement DetailsQuarterDate3/20/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsNuCana's next earnings date is estimated for Monday, November 24, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile NuCana Earnings HeadlinesNuCana (NASDAQ:NCNA) Shares Down 2% - Here's WhyOctober 21 at 2:57 AM | americanbankingnews.comNuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitorsOctober 19 at 12:11 AM | msn.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.October 21 at 2:00 AM | Crypto 101 Media (Ad)NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ...October 18 at 2:07 PM | finance.yahoo.comNuCana announces publication of new data for NUC-3373October 14, 2025 | msn.comNuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 TherapyOctober 14, 2025 | markets.businessinsider.comSee More NuCana Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email. Email Address About NuCanaNuCana (NASDAQ:NCNA) plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications. At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients. Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.View NuCana ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings O'Reilly Automotive (10/22/2025)Lam Research (10/22/2025)CME Group (10/22/2025)Tesla (10/22/2025)Barclays (10/22/2025)AT&T (10/22/2025)Kinder Morgan (10/22/2025)Boston Scientific (10/22/2025)Amphenol (10/22/2025)Vertiv (10/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
